Member Info for Uncanny

Scroll to video at the bottom.

Https://www.linkedin.com/posts/mark-eccleston-48382a_update-on-the-launch-of-blue-ribbon-bio-activity-7366859035335163910-DR4G?utm_source=share&utm_medium=member_ios&rcm=ACoAAA1LIgwBr8suZ6-q_42u9B82OT6Z-mDlizk

Only one left on the offer at 0.65p so hopefully we have the start of our change in sentiment!

Well said Minni too!

GLA NAI DYOR

Https://www.linkedin.com/posts/mark-eccleston-48382a_3d-cultures-of-prostate-cancer-cells-cultured-activity-7365812429349343232-vJut?utm_source=share&utm_medium=member_ios&rcm=ACoAAA1LIgwBr8suZ6-q_42u9B82OT6Z-mDlizk

Slug

Indeed Paten.... ME = credit where credit is due as he is pulling all the pieces together now and a huge market for a small co. like VAL.

Cant believe people whinging that things are slow after a huge sluf of RNS's with the behemoth news still to come!

Sorry breast cancer (not cancel), most notably No.1 and 2 on the list and particularly No.1 as this is AZN who our CLX inventor now works for!

Pretty chunky deal sizes hey?

;)

A little dated but here is an example of some of the largest cancel related deals in 2020 l have found, with particular note of the breast cancer deals I.e. CLX001:

https://www.fiercebiotech.com/special-report/top-15-biopharma-licensing-deals-2020

Https://www.linkedin.com/posts/mark-eccleston-48382a_do-social-hierarchies-influence-how-dogs-activity-7361882370561503234-F48u?utm_source=share&utm_medium=member_ios&rcm=ACoAAA1LIgwBr8suZ6-q_42u9B82OT6Z-mDlizk

Https://www.linkedin.com/posts/mark-eccleston-48382a_im-happy-to-share-that-im-starting-a-new-activity-7361307081255124992-2_hc?utm_source=share&utm_medium=member_ios&rcm=ACoAAA1LIgwBr8suZ6-q_42u9B82OT6Z-mDlizk

Good find guys 👍

“To top it all, in the webinar Mark admitted discussions regarding early partnering had already taken place with more planned.

GLA, DYOR, AIMO”

Https://www.linkedin.com/posts/mark-eccleston-48382a_%F0%9D%97%A2%F0%9D%97%BF%F0%9D%97%B4%F0%9D%97%AE%F0%9D%97%BB%F0%9D%97%BC%F0%9D%97%B6%F0%9D%97%B1%F0%9D%98%80-%F0%9D%97%94%F0%9D%97%BF%F0%9D%97%B2-%F0%9D%98%81%F0%9D%97%B5%F0%9D%97%B2-%F0%9D%97%99%F0%9D%98%82%F0%9D%98%81%F0%9D%98%82-activity-7360341571260542976-FSqc?utm_source=share&utm_medium=member_ios&rcm=ACoAAA1LIgwBr8suZ6-q_42u9B82OT6Z-mDlizk

Https://www.linkedin.com/posts/mark-eccleston-48382a_preclinicalresearch-3dbioprinting-nams-activity-7359252368464486400-h9dV?utm_source=share&utm_medium=member_ios&rcm=ACoAAA1LIgwBr8suZ6-q_42u9B82OT6Z-mDlizk

Don’t be a dxxx Rat, l quite clearly said it obviously didn’t materialise - my focus was on the value that their scientific team saw in 201’s commercialisation. The raising of funds was their issue!

Again throwing FUD.

Over and out and 6.40 here in Barbados so enjoy the rest of your day all.

Don’t be blinkered, albeit it didn’t materialise but why were THX prepared to pay $61.5mn plus $37.5mn for each new addition plus $2.2mn.

Now combined with new peptide CLX and rolled out in a new 20 year patent….. well the value should in theory be much higher!

Over to you ME and stop spreading FUD Rat.

Also Rat you don’t know what you are talking about. A phase 1 trial is about safety - which was proved it was good by stating 201 didn’t have any serious adverse events!

The 40p shares were probably Viera’s shares he bought! LOL

You don’t buy your shares from Valirx!

When buying in the stock market…. Caveat emptor!

Don’t blame anyone except yourself - run stop losses, DYOR and FFS do not use a BB like this to base your investment decisions.

GLA DYOR NAI

Nail on the head “the past is no guide to the future”.

Sadly many here still living in the past, naming no names!

Lol, so the new 201 / CLX peptide is a waste of time with 20 year patent? LOL